Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

HIV

PrEP trial to be run in Wales despite uncertainty from All Wales Medicines Strategy Group

Vaughan Gething, Welsh health secretary

Source: Nick Treharne

Gething says there is no doubt that Truvada reduces rates of HIV infection and that the new study will indicate how it could and should be provided across Wales

A Wales-wide study to make the antiretroviral combination treatment Truvada (emtricitabine and tenofovir disoproxil; Gilead Sciences) available for pre-exposure prophylaxis (PrEP) against HIV infection has been announced by Vaughan Gething, Welsh health secretary.

The announcement was made on 28 April 2017, just two days after the All Wales Medicines Strategy Group (AWMSG) concluded that Truvada should not be recommended for NHS use in Wales because its cost effectiveness has not been proven.

Commenting on the three-year study, which will start in summer 2017, Gething says: “There is no doubt that Truvada reduces rates of HIV infection when taken correctly and, supported by wider, preventative sexual health services, can help to reduce overall HIV transmission and infection rates. This is the advice of the World Health Organization.

“The study will help us to learn how best to provide the preventative treatment to reduce the risk of HIV transmission in Wales and answer some of the questions raised by the AWMSG around incidence rates.

“The [AWMSG] is a highly regarded, independent expert group. I acknowledge their advice that there are uncertainties regarding cost-effectiveness… I am asking Public Health Wales and the HIV Expert Group to work together to deliver the study.”

NHS England announced a similar trial in December 2016. In Scotland, however, the NHS use of Truvada for PrEP was approved by the Scottish Medicines Consortium earlier in April 2017. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202704

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Vaughan Gething, Welsh health secretary

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.